MaxCyte, Inc. MaxCyte to Present at BIO-Europe 2019
November 07 2019 - 2:01AM
RNS Non-Regulatory
TIDMMXCT
MaxCyte, Inc.
07 November 2019
MaxCyte to Present at BIO-Europe 2019
Gaithersburg, Maryland - 07 November 2019 - MaxCyte (LSE: MXCT,
MXCS), the global cell-based therapies and life sciences company,
announces that President and Chief Executive Officer Doug Doerfler
will present on the Company's CARMA(TM) cell-therapy platform at
the annual BIO Europe conference on 13 November 2019 at Hamburg
Messe, Hamburg, Germany.
The presentation, which will take place at 10:30 a.m. CET in
Hall B1, Room 6, will focus on MaxCyte's position at the forefront
of the development of next generation cell-based medicines with the
proprietary CARMA platform.
CARMA is MaxCyte's clinical-stage, non-viral, mRNA-based cell
therapy platform that allows for the transfection of mRNA into
cells and provides a simple, rapid-to-manufacture,
dose-controllable product. CARMA requires less than one day for
manufacture therapies for patients, where existing CAR-T therapies
require one to two weeks or more to manufacture. MaxCyte's
wholly-owned lead CARMA candidate, MCY-M11, is currently being
evaluated in a Phase I clinical trial in patients with advanced
ovarian cancer and peritoneal mesothelioma.
About MaxCyte
MaxCyte is a clinical-stage global cell-based therapies and life
sciences company applying its proprietary cell engineering platform
to deliver the advances of cell-based medicine to patients with
high unmet medical needs. MaxCyte is developing novel CARMA
therapies for its own pipeline, with its first drug candidate in a
Phase I clinical trial. CARMA is MaxCyte's mRNA-based proprietary
therapeutic platform for autologous cell therapy for the treatment
of solid cancers. In addition, through its life sciences business,
MaxCyte leverages its Flow Electroporation Technology to enable its
biopharmaceutical partners to advance the development of innovative
medicines, particularly in cell therapy. MaxCyte has placed its
flow electroporation instruments worldwide, including with all of
the top ten global biopharmaceutical companies. The Company now has
more than 80 partnered programme licenses in cell therapy with more
than 45 licensed for clinical use, including six announced
commercial licenses with aggregate potential milestones of more
than $450m. With its robust delivery technology platform, MaxCyte
helps its partners to unlock the full potential of their products.
For more information, visit www.maxcyte.com.
For further information, please contact:
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Ron Holtz, Chief Financial Officer +1 301 944 1660
Financial PR Adviser
Consilium Strategic Communications +44 (0)203 709 5700
Mary-Jane Elliott maxcyte@consilium-comms.com
Chris Welsh
Sukaina Virji
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct
Authority to act as a Primary Information Provider in the United
Kingdom. Terms and conditions relating to the use and distribution
of this information may apply. For further information, please
contact rns@lseg.com or visit www.rns.com.
END
NRABFBJTMBTMTIL
(END) Dow Jones Newswires
November 07, 2019 02:01 ET (07:01 GMT)
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jun 2024 to Jul 2024
Maxcyte (LSE:MXCT)
Historical Stock Chart
From Jul 2023 to Jul 2024